Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 8/20 | 0.40 |
| ▸ | GLP1R | P43220 | 3/20 | 0.39 |
| ▸ | GIPR | P48546 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22902068 | 0.83 | NOTUM (0.50) | NOTUM | |
| SCHEMBL24908516 | 0.82 | EPHX2 (0.42) | CASRNTRK1FLT3EPHX2GCGR | |
| SCHEMBL27498530 | 0.82 | EPHX2 (0.63) | NOTUMEPHX2 | |
| SCHEMBL15119356 | 0.81 | KDM5B (0.43) | NOTUMGRM4 | |
| SCHEMBL24908625 | 0.80 | NPBWR1 (0.49) | — | |
| SCHEMBL26051361 | 0.80 | MAPT (0.42) | FLT3NOTUM | |
| SCHEMBL19531652 | 0.80 | MELK (0.42) | NOTUMGRM4 | |
| SCHEMBL27496862 | 0.78 | NOTUM (0.44) | NTRK1FLT3NOTUMEPHX2GCGR | |
| SCHEMBL12351974 | 0.78 | GAA (0.53) | HSP90AA1GRM4 | |
| SCHEMBL2609437 | 0.75 | MAPKAPK2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1218472-A | Pharmaceutically useful compounds | ASTRA PHARMA PROD (GB) | 1999-06-02 | — | — | CN | claimed |
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | CASR 1121/4885NTRK1 1669/4885FLT3 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.